Physician profile
Francis Constantine
NPI 1457340432
$1,512.00
in general payments reported to CMS, 2019-2025
18 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $168 · 2021: $11.56 · 2022: $23.42 · 2023: $212 · 2024: $150 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $363.53 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $232.96 | 2019-2024 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.99 | 2019-2023 | Jardiance, Synjardy |
| Novo Nordisk INC | $118.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $95.73 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $94.29 | 2019-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $79.52 | 2019-2025 | Spravato |
| Lilly USA, LLC | $79.30 | 2019-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $67.01 | 2019-2020 | |
| Abbott Laboratories | $59.73 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $38.65 | 2024-2025 | |
| Indivior INC. | $31.66 | 2025 | Sublocade |
| Merck Sharp & Dohme LLC | $27.11 | 2019 | |
| Amarin Pharma, INC. | $25.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.05 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $20.73 | 2023 | Heplisav-B |
| Biogen, INC. | $18.45 | 2019 | |
| Amgen INC. | $14.22 | 2025 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Constantine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.